Sitafloxacin and garenoxacin may overcome the antibiotic resistance of helicobacter pylori with gyrA mutation

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 4, 2009, Pages 1720-1721

  Suzuki, Hidekazu ^a   Nishizawa, Toshihiro ^a   Hibi, Toshifumi ^b   Muraoka, Hiroe ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LSI MEDIENCE CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; GARENOXACIN; GATIFLOXACIN; LEVOFLOXACIN; RABEPRAZOLE; SITAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL STRAIN; DRUG ACTIVITY; ERADICATION THERAPY; GENE; GENE MUTATION; GENE SEQUENCE; GRAM POSITIVE BACTERIUM; GYRA GENE; HELICOBACTER PYLORI; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HELICOBACTER PYLORI; MUTATION;

EID: 65649121211     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00049-09     Document Type: Letter

References (10)

1. Fujimura, S., S. Kato, K. linuma, and A. Watanabe.2004. In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strainsisolated from children. J. Med. Microbiol. 53:1019-1022. (Pubitemid 39391971)
2. Gisbert, J. P., M. Castro-Fernandez, F. Bermejo, et al. 2006. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am. J. Gastroenterol. 101:243-247. (Pubitemid 43381662)
3. Moore, R. A., B. Beckthold, S. Wong, A. Kureishi, and L. E. Bryan. 1995. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob. Agents Chemother. 39:107-111.
4. National Committee for Clinical Laboratory Standards. 2004. Methods fordilution antimicrobial susceptibility tests for bacteria that grow aerobically.Approved standard.-sixth edition, M7-A6. National Committee for Clinical Laboratory Standards, Villanova, PA.
5. Nishizawa, T., H. Suzuki, K. Kurabayashi, T. Masaoka, H. Muraoka, M. Mori, E. Iwasaki, I. Kobayashi, and T. Hibi. 2006. Gatifloxacin resistance and mutations in gyrA after unsuccessful Helicobacter pylori eradication in Japan. Antimicrob. Agents Chemother. 50:1538-1540.
6. Nishizawa, T., H. Suzuki, I. Nakagawa, E. Iwasaki, T. Masaoka, and T. Hibi. 2008. Gatifloxacin-based triple therapy as a third-line regimen for Helico-bacter pylori eradication. J. Gastroenterol. Hepatol. 23:S167-S170.
7. Sánchez, J. E., N. G. Sáenz, M. R. Rincón, T. T. Martin, E. G. Sánchez, andM. J. Martinez. 2000. Susceptibility of Helicobacter pylori to mupirocin,oxazolidinones, quinupristin/dalfopristin and new quinolones. J. Antimicrob.Chemother. 46:283-285. (Pubitemid 30639300)
8. Sharara, A. L, H. F. Chaar, E. Aoun, H. Abdul-Baki, G. F. Araj, and S. S. Kanj. 2006. Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. Helicobacter11:231-236. (Pubitemid 44051348)
9. Suzuki, H., T. Hibi, and B. J. Marshall. 2007. Helicobacter pylori: present status and future prospects in Japan. J. Gastroenterol. 42:1-15. (Pubitemid 46357245)
10. Tankovic, J., C. Lascols, Q. Sculo, J. C. Petit, and C. J. Soussy. 2003. Singleand double mutations in gyrA but not in gyrB are associated with low-and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 47:3942-3944. (Pubitemid 37485011)